Aclaris Therapeutics vs Eloxx Pharmaceuticals
ACRS and ELOX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and ELOX compare
Aclaris Therapeutics is the larger company, worth 10 times as much as Eloxx Pharmaceuticals ($531M against $51.5M).
Aclaris Therapeutics grew revenue faster over the last twelve months (−51.0% versus −100% for Eloxx Pharmaceuticals).
Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 5 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | ELOX |
|---|---|---|
| Size and price | ||
| Market cap | $531M | $51.5M |
| Share price | $3.60 | $12.75 |
| Change, 1 year | 55.4% | 1158990% |
| Change, 5 years | −71.4% | −97.9% |
| Beta (5Y) | 0.96 | – |
| Employees | 73 | 7 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 64.6× | – |
| P/B | 4.3× | 1.1× (better) |
| FCF yield | −11.7% | – |
| Fair value | $1.42 | – |
| Margin of safety | −155% | – |
| Growth | ||
| Revenue growth (TTM) | −51.0% (better) | −100% |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.5% | – |
| Operating margin | −1050% | – |
| Net margin | −921% | – |
| FCF margin | −757% | – |
| Return on equity | −59.1% | −54.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.46 | 3.74 (better) |
| Altman Z-score | −3.16 (better) | −4.46 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 71.8% |
| Held by insiders | 13.3% | 42.6% |
| Insider net buying, 12 months | −$1.4M | – |
| Short interest, % of float | 9.1% | 2.3% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.